An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Abiomed, a leading provider of circulatory support medical devices, will release its second-quarter fiscal 2022 financial results on October 28, 2021. A conference call is set for 8:00 a.m. ET on the same day, hosted by CEO Michael R. Minogue and CFO Todd Trapp. Investors can tune in via webcast or by phone. A replay will be available from 11:00 a.m. ET on October 28 through 10:00 a.m. ET on November 4. The company highlights its focus on product development and commercial growth, but risks due to external factors remain.
Positive
Scheduled release of second-quarter fiscal 2022 results, indicating ongoing transparency with investors.
The conference call allows for direct engagement between company leadership and shareholders.
Negative
Potential risks from external factors such as COVID-19 impact on business operations and product development.
DANVERS, Mass.--(BUSINESS WIRE)--
Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, October 28, 2021, the Company will release financial results for the second quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, October 28, 2021 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call.
To listen to the call live, please tune into the webcast via https://investors.abiomed.com/events-presentations or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11:00 a.m. ETOctober 28, 2021 through 10:00 a.m. ET on November, 4, 2021. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 5159829.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, including with respect to Abiomed's development of existing and new products, the Company's commercial growth, future business opportunities and pending regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements due to a number of factors, including uncertainties related to the scope, extent and duration of the impact of the COVID-19 pandemic, development, testing and related regulatory approvals, including the possibility of future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological changes, governmental requirements, litigation, future capital requirements and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K and subsequent filings with the SEC. Readers of this press release are advised not to evaluate forward-looking statements, which reflect information available only as of the date of this release, as reliable information. The Company is under no obligation to release updates to these forward-looking statements to reflect events or circumstances occurring after the date of the release or as a result of the impact of unforeseen events.
